The Cytotoxic Effect of Septic Plasma on Healthy RBCs: Is Eryptosis a New Mechanism for Sepsis?


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
16 Sep 2023
Historique:
received: 04 08 2023
revised: 11 09 2023
accepted: 14 09 2023
medline: 29 9 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

Sepsis is a life-threatening multiple-organ dysfunction induced by infection and is one of the leading causes of mortality and critical illness worldwide. The pathogenesis of sepsis involves the alteration of several biochemical pathways such as immune response, coagulation, dysfunction of endothelium and tissue damage through cellular death and/or apoptosis. Recently, in vitro and in vivo studies reported changes in the morphology and in the shape of human red blood cells (RBCs) causing erythrocyte death (eryptosis) during sepsis. Characteristics of eryptosis include cell shrinkage, membrane blebbing, and surface exposure to phosphatidylserine (PS), which attract macrophages. The aim of this study was to evaluate the in vitro induction of eryptosis on healthy RBCs exposed to septic plasma at different time points. Furthermore, we preliminary investigated the in vivo levels of eryptosis in septic patients and its relationship with Endotoxin Activity Assay (EAA), mortality and other biological markers of inflammation and oxidative stress. We enrolled 16 septic patients and 16 healthy subjects (no systemic inflammation in the last 3 months) as a control group. At diagnosis, we measured Interleukin-6 (IL-6) and Myeloperoxidase (MPO). For in vitro study, healthy RBCs were exposed to the plasma of septic patients and CTR for 15 min, 1, 2, 4 and 24 h. Morphological markers of death and eryptosis were evaluated by flow cytometric analyses. The cytotoxic effect of septic plasma on RBCs was studied in vitro at 15 min, 1, 2, 4 and 24 h. Healthy RBCs incubated with plasma from septic patients went through significant morphological changes and eryptosis compared to those exposed to plasma from the control group at all time points (all,

Identifiants

pubmed: 37762478
pii: ijms241814176
doi: 10.3390/ijms241814176
pmc: PMC10531772
pii:
doi:

Substances chimiques

Interleukin-6 0
Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Cell Physiol Biochem. 2005;15(5):195-202
pubmed: 15956782
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Leukemia. 2009 Nov;23(11):2102-8
pubmed: 19626047
J Immunol Methods. 1998 Mar 15;212(2):169-85
pubmed: 9672205
Shock. 2020 Nov;54(5):606-614
pubmed: 32516170
Intensive Care Med Exp. 2017 Sep 15;5(1):43
pubmed: 28916973
Cell Physiol Biochem. 2016;39(5):1977-2000
pubmed: 27771701
Annu Rev Immunol. 1990;8:253-78
pubmed: 2188664
Crit Care Med. 2009 Apr;37(4):1244-50
pubmed: 19242346
J Mol Med (Berl). 2007 Mar;85(3):273-81
pubmed: 17180345
Acta Physiol (Oxf). 2006 May-Jun;187(1-2):191-8
pubmed: 16734755
Diagnostics (Basel). 2022 Dec 27;13(1):
pubmed: 36611371
Crit Care. 2012 Jul 16;16(4):R125
pubmed: 22800762
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
J Clin Med. 2022 Nov 23;11(23):
pubmed: 36498493
Transfus Med Hemother. 2012 Oct;39(5):308-14
pubmed: 23801921
Cell Physiol Biochem. 2011;28(5):847-56
pubmed: 22178937
Int J Biochem Cell Biol. 2012 Aug;44(8):1236-43
pubmed: 22561748
J Leukoc Biol. 2005 May;77(5):598-625
pubmed: 15689384
Inflammation. 2018 Oct;41(5):1569-1581
pubmed: 29956069
Am J Physiol Heart Circ Physiol. 2020 Sep 1;319(3):H705-H721
pubmed: 32762560
Cell Physiol Biochem. 2017;43(2):431-444
pubmed: 28922657
J Intensive Care Med. 2013 Sep-Oct;28(5):307-13
pubmed: 22809690
J Infect Dis. 2004 Aug 1;190(3):527-34
pubmed: 15243928
J Clin Med. 2022 Sep 10;11(18):
pubmed: 36142976
Sci Transl Med. 2010 Sep 29;2(51):51ra71
pubmed: 20881280
Chest. 1991 Jan;99(1):169-75
pubmed: 1984950
Crit Care Med. 2009 Dec;37(12):3041-6
pubmed: 19770749
Annu Rev Pathol. 2011;6:19-48
pubmed: 20887193
J Inflamm (Lond). 2010 Jan 08;7:1
pubmed: 20148136
J Biol Chem. 1998 Aug 28;273(35):22719-28
pubmed: 9712903
Front Med (Lausanne). 2021 May 14;8:628302
pubmed: 34055825
Immunol Today. 1988 May;9(5):137-9
pubmed: 3076767
Cell Physiol Biochem. 2008;22(5-6):373-80
pubmed: 19088418
Cell Host Microbe. 2010 Dec 16;8(6):544-50
pubmed: 21147468
JAMA. 2009 Jun 17;301(23):2445-52
pubmed: 19531784
Tzu Chi Med J. 2021 Oct 05;34(2):125-133
pubmed: 35465286
Blood Purif. 2019;48(4):351-357
pubmed: 31291616
Trials. 2014 Jun 11;15:218
pubmed: 24916483
Cochrane Database Syst Rev. 2019 Apr 30;4:CD011811
pubmed: 31038735
Blood Purif. 2016;41(4):317-23
pubmed: 26848873
Biomed Res Int. 2015;2015:513518
pubmed: 25821808
Cell Physiol Biochem. 2010;26(1):21-8
pubmed: 20502001
Antioxid Redox Signal. 2014 Jul 1;21(1):138-53
pubmed: 24359125
Int Urol Nephrol. 2022 Nov;54(11):2919-2928
pubmed: 35469112
Sci Rep. 2016 Aug 26;6:32188
pubmed: 27561337

Auteurs

Matteo Marcello (M)

Department of Nephrology, Dialysis and Transplant, St Bortolo Hospital, 36100 Vicenza, Italy.
IRRIV-International Renal Research Institute, 36100 Vicenza, Italy.

Grazia Maria Virzì (GM)

Department of Nephrology, Dialysis and Transplant, St Bortolo Hospital, 36100 Vicenza, Italy.
IRRIV-International Renal Research Institute, 36100 Vicenza, Italy.

Davide Marturano (D)

Department of Nephrology, Dialysis and Transplant, St Bortolo Hospital, 36100 Vicenza, Italy.
IRRIV-International Renal Research Institute, 36100 Vicenza, Italy.
Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, 35100 Padova, Italy.

Massimo de Cal (M)

Department of Nephrology, Dialysis and Transplant, St Bortolo Hospital, 36100 Vicenza, Italy.
IRRIV-International Renal Research Institute, 36100 Vicenza, Italy.

Nicola Marchionna (N)

Department of Nephrology, Dialysis and Transplant, St Bortolo Hospital, 36100 Vicenza, Italy.
IRRIV-International Renal Research Institute, 36100 Vicenza, Italy.

Luca Sgarabotto (L)

Department of Nephrology, Dialysis and Transplant, St Bortolo Hospital, 36100 Vicenza, Italy.
IRRIV-International Renal Research Institute, 36100 Vicenza, Italy.

Silvia De Rosa (S)

Centre for Medical Sciences-CISMed, University of Trento, Via S. Maria Maddalena 1, 38122 Trento, Italy.
Anesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, 38122 Trento, Italy.

Claudio Ronco (C)

IRRIV-International Renal Research Institute, 36100 Vicenza, Italy.

Monica Zanella (M)

Department of Nephrology, Dialysis and Transplant, St Bortolo Hospital, 36100 Vicenza, Italy.
IRRIV-International Renal Research Institute, 36100 Vicenza, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH